Clinical Trial Update: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating bortezomib with sorafenib tosylate in newly diagnosed acute myeloid leukemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Leukemia Cutis
• Myeloid Neoplasm
• Myeloid Sarcoma

Drugs mentioned

• Bortezomib (bortezomib)
• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acute Myeloid Leukemia, Leukemia Cutis | Phase 3 | Status: COMPLETED | Results posted: 2020-07-07